ADPT vs INCY
Adaptive Biotechnologies Corporation vs Incyte — AI-powered side-by-side comparison
ADPT
Adaptive Biotechnologies Corporation
59
Watch
VS
| Metric | ADPT | INCY |
|---|
| AI Score |
59
|
72
|
| Price |
$25.39
|
$121.08
|
| P/E Ratio |
-62.32×
|
14.89×
|
| ROE |
-27.2%
|
24.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
75.4%
|
92.6%
|
| Debt / Equity |
2.87×
|
0.01×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
67.3
|
56.2
|
| Beta |
2.088
|
0.769
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for ADPT versus INCY.
INCY leads by 13 points.
INCY scores 72/100 (Buy) versus ADPT at 59/100 (Watch).
ADPT Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — revenue growing 50.1% yoy -- genuine top-line momentum. Value Analyst remains cautious — price-to-book of 11.3x prices in significant intangible value. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Revenue growing 50.1% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Price-to-book of 11.3x prices in significant intangible value — Value
- ROE of only -32.6% -- cheap may mean cheap for a reason — Value
- Weekly RSI at 85 -- overbought on the larger timeframe too — Technical
INCY Committee View
100% agreement
6 analysts
The primary driver is revenue growing 26.9% yoy -- genuine top-line momentum. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 29.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 26.9% YoY -- genuine top-line momentum — Growth
- EPS growing 80.3% YoY — Growth
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical